Hotspots and frontiers in chronic postoperative pain: a bibliometric analysis and review (2004-2025)
Quick Take: Bibliometric mapping of two decades of CPOP research reveals a decisive shift: we are moving away from treating "surgical scars" and toward managing "neural signatures."
💡 Clinical Impact
- Mechanistic Why: CPOP is increasingly understood not as delayed healing, but as a maladaptive neuroplastic event. Research "hotspots" in neuroinflammation and genetic predisposition suggest that the surgical insult triggers a systemic inflammatory cascade that "primes" the central nervous system, leading to permanent central sensitization in vulnerable patients.
- Systemic Benefit: Identifying these biological frontiers allows us to move from reactive analgesia (opioids) to proactive stratification. By recognizing the "high-risk" neural profile preoperatively, we can implement aggressive, multi-modal preventive blocks that "shield" the nervous system from the initial surgical trauma.
📊 Evidence Breakdown
- Evidence Grade: 🟡 7/10 (Bibliometric/Systematic Review)
- Analysis: This is a "map of the maps." It is statistically robust in identifying where the money and minds are going, but it provides a 7/10 signal because it tracks volume of research rather than the clinical success of those frontiers. It highlights a massive "Translational Chasm": we are brilliant at identifying the genes for pain, but still average at preventing it in the recovery room.
Note: The "noise" here is the lag time. A research "hotspot" in 2026 typically takes 5–10 years to become a standard-of-care protocol in a community hospital.
🩺 Practice Recommendation Status: [Early Signal / Translational Awareness]
Monday Morning Action
- Transition to "Risk-Based" Consent: When discussing surgery, move beyond "infection and bleeding." Incorporate CPOP risk—especially for high-risk procedures like thoracotomy or limb amputation—and document the patient's baseline psychological and inflammatory status.
- The "Pre-emptive" Mindset: Since neuroinflammation is a confirmed hotspot, prioritize multi-modal non-opioid stacks (e.g., gabapentinoids, ketamine, or regional blocks) before the first incision to dampen the "wind-up" effect described in the literature.
- Identify "Yellow Flags": While we wait for genetic testing to go mainstream, use existing clinical proxies for central sensitization, such as widespread pain at other sites or significant pre-operative anxiety, as indicators for more intensive perioperative pain management.
- Audit the "Chronic" Outcome: Does your department track pain at the 3-month or 6-month mark? If not, initiate a pilot to follow up on high-risk patients. You cannot manage a "translational gap" you aren't measuring.